Breaking News: Eli Lilly Increases Mounjaro Prices as Trump Urges Pharma Change

Thursday, 14 August 2025, 16:00

Breaking news as Eli Lilly hikes the price of its diabetes drug Mounjaro in the UK, coinciding with Donald Trump's push for the health care industry to lower U.S. drug prices. This move highlights the ongoing tensions in the pharmaceutical market. The implications for biotech and the pharmaceutical sectors are significant as the former president ramps up his campaign for price alignment.

Cnbc — Breaking News: Eli Lilly Increases Mounjaro Prices as Trump Urges Pharma Change

Breaking news: Eli Lilly, a major player in the health care industry, has announced a price increase for its diabetes drug Mounjaro in the UK. This decision comes as former President Donald Trump intensifies his pressure on pharmaceuticals to lower drug costs in the United States.

This price hike follows Trump's criticisms of drug companies for maintaining high prices domestically while increasing costs abroad under the most favored nation policy. The biotechnology sector is closely watching these developments, which may influence policy changes regarding drug pricing.

Implications for Biotech and Pharmaceuticals

The actions of Eli Lilly may set a precedent for the health care industry, with potential ripple effects in pricing strategies across the biotech and pharmaceuticals landscape.

Trump's Influence on Drug Pricing

As Donald Trump continues to voice his concerns over drug pricing, pharmaceutical companies, including Eli Lilly, find themselves at a crossroads, balancing profits with public scrutiny.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.